ClinicalTrials.gg
Active, not recruitingNCT05669755REDEFINE 3Updated Aug 31, 2026

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

A Phase 3 interventional study of Cagrilintide and Semaglutide in Cardiovascular Disease, sponsored by Novo Nordisk A/S. Active, not recruiting at 633 sites in 25 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,101
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

02

Conditions studied

  • Cardiovascular Disease
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 7,101 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age above or equal to 55 years at the time of signing
  • (BMI) greater than or equal to (>=) 25.0 kilograms per meter square (kg/m\^2)
  • Established CVD as evidenced by at least one of the following:

    1. Prior myocardial infarction
    2. Prior stroke (ischemic or haemorrhagic stroke)
    3. Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:

      1. Intermittent claudication with an ankle-brachial index (ABI) less than (\<) 0.85 at rest
      2. Intermittent claudication with a >= 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computed tomography (CT) angiography or Doppler ultrasound
      3. Prior revascularization procedure of a lower extremity peripheral artery
      4. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)

For participants with T2D at screening the following inclusion criteria also apply:

  • Diagnosed with type 2 diabetes mellitus (T2D) >= 180 days before screening
  • 6.5%-10% (47-86 millimoles per mole [mmol/mol]) (both inclusive), as measured by central laboratory at screening
  • Treatment with either:

    1. Lifestyle intervention alone
    2. 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), dipeptidyl peptidase 4 (DPP4)-inhibitors, thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local label
    3. Basal insulin alone or in combination with up to two marketed OADs, all according to local label

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction, stroke, hospitalization for unstable angina pectoris or within 60 days before screening
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
  • Heart failure classified as being in (NYHA) Class IV at screening
  • Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
  • End stage renal disease defined as estimated (eGFR) \< 15 millileters per minutes per 1.73\^2 (mL/min/1.73 m\^2), as measured by the central laboratory at screening
  • Chronic or intermittent haemodialysis or peritoneal dialysis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,101 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.

    Drug: Placebo

Interventions

  • Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

  • Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.

  • DrugPlacebo

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke

    Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

Secondary outcomes

  1. Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death

    CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  2. Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death

    CKD-EPI is Chronic Kidney Disease Epidemiology Collaboration. Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  3. Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation

    Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  4. Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke

    Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  5. Time to first occurrence of myocardial infarction (fatal and non-fatal)

    Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  6. Time to first occurrence of stroke (fatal and non-fatal)

    Measured in days.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  7. Change in eGFRcr (CKD-EPI)

    Measured in milliliter per min per 1.73 square meter (mL/min/1.73m\^2).

    Time frame: From baseline (week 0) to 120 weeks

  8. Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)

    Measured in ratio.

    Time frame: From baseline (week 0) to 120 weeks

  9. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to 120 weeks

  10. Change in waist circumference

    Measured in centimeters (cm).

    Time frame: From baseline (week 0) to 120 weeks

  11. Change in waist-to-height ratio

    Measured in ratio.

    Time frame: From baseline (week 0) to 120 weeks

  12. Change in systolic blood pressure (SBP)

    Measured in millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to 120 weeks

  13. Change in diastolic blood pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to 120 weeks

  14. Ratio to baseline in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids

    Measured in ratio.

    Time frame: From baseline (week 0) to 120 weeks

  15. Change in glycated haemoglobin (HbA1c)

    Measured in percentage-points.

    Time frame: From baseline (week 0) to 120 weeks

  16. Number of treatment emergent serious adverse events (TESAEs)

    Measured in count of events.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  17. Number of event adjudication committee (EAC)-confirmed malignant neoplasms

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

  18. Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (up to 242 weeks or more)

07

Study locations

633 sites

Showing the first 100 of 633 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Sep 2027, 54 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's planned 54 months is above that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 3, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Oct 14, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669755
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Mar 1, 2023
Primary completion
Sep 1, 2027 (estimated)
Completion
Oct 14, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion